The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Lilly recently announced news that could solve a big problem.
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
These two pharma stocks have followed distinct paths of late. Which is the better investment?
It's not only spending its capital on developing new drugs.
These stocks probably won't be getting much cheaper.
Low risk and high-reward potential? These stocks could offer both.
Cardiol Therapeutics (CRDL), a clinical-stage life sciences company, is researching and developing new drugs to fight inflammation and scarring in the heart. Their main drug, CardiolRx™, is b